Proxor 100/6 & 200/6
Proxor® is a beclometasone/formoterol pressurised metered-dose inhaler (pMDI) which is therapeutically equivalent to Fostair® pMDI for formulation and device characteristics.1
Proxor® (beclometasone/formoterol) indications
For use in adults only.
Asthma
Proxor® 100/6 and 200/6: Regular treatment of asthma where use of a combination product is appropriate: Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β2-agonist; Patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonists.
Chronic Obstructive Pulmonary Disease (COPD)
Proxor® 100/6: Symptomatic treatment of severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Proxor® 100/6 is licensed for Maintenance and Reliever Therapy (MART) in asthma.
Instructions for reporting Adverse Events can be found in the footer of this page. Prescribing information is available here.
Unlock £201m of savings with Proxor®
Annual estimated reduction in prescribing spend of £201m for the NHS in the UK from using Proxor® pMDI as first choice beclometasone/formoterol inhaler.2
Equivalence to Fostair® pMDI
Proxor® pMDI is equivalent to Fostair® pMDI in terms of:1
- Active ingredient and excipients
- Delivered dose per metered counter
- Inhaling technique
- Therapeutic effect and device characteristics
Demonstration devices are also available
Device Characteristics
1. Cap | 2. Mouthpiece | 3. Base
4. Push button | 5. Canister | 6. Counter
Implementation Support
We’re here to support you all the way through the implementation process, with formulary application support documents, cost calculators for your area, letters as well as materials for both healthcare professionals and patients.
Formulary Review Process:
-
- Formulary application support document
Request document - Tailored cost-savings report detailing savings for your area
Request report - Price & stock commitment letter
- Pharmacy letter – introduction to formulary
- Formulary application support document
For Healthcare Professionals:
- Product information leaflets
- Demonstration devices for training
Request demo devices
For Patients
- Device demonstration video
- Leaflet with instructions for use
- Letter to explain change in inhaler
- Website
Visit patient website
Certified As Carbon Neutral
Both Proxor® 100/6 and 200/6 pMDIs are certified as Carbon Neutral products.3,4 This is in alignment with NHS’s goal to achieve net-zero carbon emissions.5
References
- STADA UK Ltd. 2024. Data on File. Proxor Pharmaceutical Development.
- STADA UK Ltd. 2024. Data on File. Based on indicative NHS list prices and IQVIA data. Access date: April 2025.
- Certifications of carbon neutrality for Proxor 100/6 and 200/6 pMDI.
- Carbon Footprint Limited. Carbon Life Cycle Assessment Report for Proxor 100/6mcg and 200/6mcg pMDI Inhalers.
- NHS England. 2021. Delivering a ‘Net Zero’ National Health Service. Access date: April 2025.
